Background Pancreatic cancer retains a poor prognosis among the gastrointestinal cancers.
It affects 230,000 individuals worldwide, has a very high mortality rate, and remains one of …

Background Pancreatic cancer is a complex genetic disorder that is characterized by rapid
progression, invasiveness, resistance to treatment and high molecular heterogeneity …

Introduction: Resistance to gemcitabine is common and critically limits its therapeutic
efficacy in pancreatic ductal adenocarcinoma (PDAC). Methods: We constructed 17 patient …

Overcoming chemoresistance of pancreatic cancer (PCa) cells should significantly extend
patient survival. The current treatment modalities rely on a variety of DNA damaging agents …

This work aimed to discover targets for combination treatment with gemcitabine in pancreatic
cancer. We selected 11 tumors from our live collection of freshly generated pancreatic …

Chemotherapy of advanced pancreatic cancer has mainly been gemcitabine-based for the
past 15 years, with only limited effect. Recently, combination therapy that also targets …

Background Among the solid tumors, human pancreatic ductal adenocarcinoma (PDAC) has
the worst prognosis. Gemcitabine is the standard first line of therapy for pancreatic cancer …

Resistance to gemcitabine is the main challenge of chemotherapy for pancreatic ductal
adenocarcinoma (PDAC). Hence, the development of a response signature to gemcitabine …

Pancreatic cancer is one of the most difficult malignancies to treat owing to the rapid
acquisition of resistance to chemotherapy. Gemcitabine, a first-line treatment for pancreatic …

Gemcitabine sensitization is important for the treatment of pancreatic cancer. We have
previously shown that DNA-dependent protein kinase catalytic subunit (DNA-PKcs) over …